Pulmonx vs NeuroPace
LUNG and NPCE side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LUNG and NPCE compare
NeuroPace is the larger company, worth 3.2 times as much as Pulmonx ($413M against $129M).
NeuroPace grew revenue faster over the last twelve months (23.0% versus −3.2% for Pulmonx).
NeuroPace keeps more of each dollar of sales as profit, with a net margin of −17.7% compared with −47.9% at Pulmonx.
Pulmonx scores higher on the StockData Score (6 against 5 for NeuroPace), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LUNG | NPCE |
|---|---|---|
| Size and price | ||
| Market cap | $129M | $413M |
| Share price | $3.00 | $12.02 |
| Change, 1 year | 43.5% | −10.9% |
| Change, 5 years | −91.3% | 1.4% |
| Beta (5Y) | 1.75 | 1.05 |
| Employees | 296 | 209 |
| StockData Score | ||
| Total score | 6 (better) | 5 |
| Valuation score | 2 (better) | 0 |
| Growth score | 2 | 3 (better) |
| Performance score | 1 | 1 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.5× (better) | 3.9× |
| P/B | 3.8× (better) | 35.9× |
| FCF yield | −19.9% | −3.0% (better) |
| Fair value | $4.81 | $6.78 |
| Margin of safety | 37.7% (better) | −77.2% |
| Growth | ||
| Revenue growth (TTM) | −3.2% | 23.0% (better) |
| Revenue growth, 5Y average | 22.6% (better) | 19.4% |
| Profitability | ||
| Gross margin | 77.4% | 77.8% (better) |
| Operating margin | −44.4% | −9.5% (better) |
| Net margin | −47.9% | −17.7% (better) |
| FCF margin | −28.8% | −11.6% (better) |
| Return on equity | −90.3% (better) | −126% |
| Return on invested capital | −156% | −41.4% (better) |
| Financial health | ||
| Debt / equity | 1.11 (better) | 5.15 |
| Interest coverage | −9.4× | −1.6× (better) |
| Current ratio | 4.05 | 5.26 (better) |
| Altman Z-score | −5.70 | −3.79 (better) |
| Piotroski F-score | 3 | 5 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 0.00% |
| Years of dividend growth | – | 0 |
| Buyback yield | – | 0.00% |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 61.0% | 77.4% |
| Held by insiders | 16.6% | 16.6% |
| Insider net buying, 12 months | −$548K | −$399K (better) |
| Short interest, % of float | 2.2% | 3.0% |
Go deeper
- LUNG stock overview
- LUNG income statement
- LUNG valuation and score
- NPCE stock overview
- NPCE income statement
- NPCE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.